SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Reynolds Thomas C

(Last)

(First)

(Middle)

C/O TRILLIUM THERAPEUTICS INC.

2488 DUNWIN DRIVE

(Street)

MISSISSAUGA

L5L 1J9

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2021

3. Issuer Name and Ticker or Trading Symbol
Trillium Therapeutics Inc. [ TRIL ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽¹⁾	12/23/2030	Common Shares	40,000	$12.03	D
Stock Option (Right to Buy)	⁽²⁾	03/06/2024	Common Shares	6,666	$14.931⁽³⁾	D
Stock Option (Right to Buy)	⁽⁴⁾	11/01/2030	Common Shares	50,000	$12.45	D
Stock Option (Right to Buy)	⁽⁵⁾	11/01/2030	Common Shares	20,000	$12.45	D
Deferred Share Unit	⁽⁶⁾	⁽⁶⁾	Common Shares	526,866.024	⁽⁶⁾	D

Explanation of Responses:

1. 50% of the options vested immediately upon grant and the remaining options vest in equal monthly installments over the following six months.

2. 1/3 of the options vested immediately upon grant and the remaining options vest in equal annual installments over the following four years.

3. The exercise price of these options is $18.90 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.

4. Options vest in equal quarterly installments over the three years following the grant date.

5. Options vest in full on February 28, 2021.

6. Each Deferred Share Unit ("DSU") represents a contingent right to receive one common share of the Issuer (or cash in lieu of fractional DSUs) upon the termination of the grantee's service with the Issuer. All DSUs are fully vested as of the date hereof.

	/s/ James Parsons, Attorney-in-Fact	01/04/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.